TITLE

A Multidisciplinary Approach to the Management of Breast Cancer, Part 2: Therapeutic Considerations

AUTHOR(S)
Pruthi, Sandhya; Boughey, Judy C.; Brandt, Kathleen R.; Degnim, Amy C.; Dy, Grace K.; Goetz, Matthew P.; Perez, Edith A.; Reynolds, Carol A.; Schomberg, Paula J.; Ingle, James N.
PUB. DATE
September 2007
SOURCE
Mayo Clinic Proceedings;Sep2007, Vol. 82 Issue 9, p1131
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
New approaches to breast cancer treatment have enhanced clinical outcomes and patient care. These approaches include advances in breast irradiation and hormonal and systemic adjuvant therapies. In addition to the identification of new drug targets and targeted therapeutics (eg, trastuzumab), there is renewed reemphasis in the development of biomarkers for the prediction of response to therapy. One example is the pharmacogenetics of tamoxifen metabolism and the individualization of hormonal therapy. The current treatment of breast cancer continues to evolve rapidly, with new scientific and clinical achievements constantly changing the standard of care and leading to substantial reductions in breast cancer mortality. The goal of this article is to provide clinicians who care for women with breast cancer a multidisciplinary, state-of-the art approach to the treatment of these patients.
ACCESSION #
26757475

 

Related Articles

  • Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials. Rose, Carsten // Journal of Cancer Research & Clinical Oncology;Jan2008, Vol. 134 Issue 1, p7 

    For disease-free postmenopausal women with hormone-responsive breast cancer, a risk for relapse remains following 5 years of adjuvant therapy with tamoxifen. Additional therapy with tamoxifen beyond 5 years is not indicated due to a demonstrated lack of efficacy beyond this time frame. Thus,...

  • Male breast cancer: a review of clinical management. Agrawal, A.; Ayantunde, A.; Rampaul, R.; Robertson, J. // Breast Cancer Research & Treatment;May2007, Vol. 103 Issue 1, p11 

    Male breast cancer incidence is 1% of all breast cancers and is increasing. We aim to present an overview of male breast cancer with particular emphasis on clinical management. Studies were identified by an online search of literature in the MEDLINE database till June 2006 followed by an...

  • Palmar-plantar erythrodysesthesia secondary to docetaxel chemotherapy: a case report.  // Journal of Medical Case Reports;2011, Vol. 5 Issue 1, p1 

    The article presents a case study of a a 66-year-old Caucasian woman who was underwent a adjuvant docetaxel monotherapy for curing breast cancer . It informs that palmar-plantar erythrodysesthesia disease developed in the woman after the therapy. It also informs that a diagnosis revealed...

  • Diffusion-weighted MR imaging of Carmofur-induced leukoencephalopathy. Fujikawa, Akira; Tsuchiya, Kazuhiro; Katase, Shichiro; Kurosaki, Yoshihisa; Hachiya, Junichi // European Radiology;Dec2001, Vol. 11 Issue 12, p2602 

    Carmofur (1-hexylcarbamyl-5-fluorouracil), a derivative of 5-fluorouracil (5-FU), has been widely used in Japan as a postoperative adjuvant chemotherapy agent for colorectal and breast cancer. Periventricular hyperintensity on T2-weighted MR images in carmofur-induced leukoencephalopathy...

  • Breast cancer trial stopped early. Josefson, Deborah // BMJ: British Medical Journal (International Edition);04/18/98, Vol. 316 Issue 7139, p1187 

    Focuses on the breast cancer prevention trial which was halted by American investigators. Information on the participants of the study; Findings on the effect of tamoxifen and placebo; Benefits of tamoxifen; What were not studied in the trial. INSET: British researchers say the American trial...

  • Tamoxifen and thromboembolism risk: no race-related differences.  // Reactions Weekly;1/15/2005, Issue 1034, p5 

    Discusses research being done on the differences in tamoxifen-associated thromboembolism risk or tamoxifen-associated reduction in contralateral cancer. Reference to a study by W. McCaskill-Stevens et al published in the December 1, 2005 issue of the "Journal of the National Cancer Institute";...

  • Painstaking study. Beyzarov, Elena Portyansky // Drug Topics;5/1/2000, Vol. 144 Issue 9, p30 

    Focuses on the reluctance of women to participate in a trial that is set to compare tamoxifen and Evista, a drug for breast cancer prevention. Why women are not interested with the tests; Side effects of the drugs.

  • Keep taking the tablets in breast cancer. Lyon, Sue // British Journal of Hospital Medicine (17508460);Nov2009, Vol. 70 Issue 11, p618 

    Information about the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial discussed at the European Cancer Conference (ECCO)/European Society for Medical Oncology (ESMO) on September 20-24, 2009 in Berlin, Germany is presented. The topic was focused on the long-term compliance of tamoxifen...

  • A prognostic index for operable, node-negative breast cancer. Mccaiium, M; Baker, C; Gillespie, K; Cohen, B; Stewart, H; Leonard, R; Cameron, D; Leake, R; Paxton, J; Robertson, A; Purdie, C; Gould, A; Steel, M // British Journal of Cancer;5/17/2004, Vol. 90 Issue 10, p1933 

    Clinical data and samples from patients diagnosed, more than 10 years previously, with operable node-negative breast cancer (participants in the Scottish Adjuvant Tamoxifen trial), were revisited. Cases with two distinct categories of outcome were selected; more than 10 years disease-free...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics